Houston-based Clinic Seeking Kids with Migraine for Clinical Trial

NEUROCARE PLUS CURRENTLY RECRUITING CHILDREN AND ADOLESCENTS AGES 12-17 FOR A CLINICAL TRIAL EVALUATING THE SAFETY AND EFFECTIVENESS OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE

Many Parents may not Realize their Child’s Head Pain may be Migraine, Since it’s an Invisible Disease

Migraine Impacts Up to 11% of Elementary School-Age Children and Up to 15% of High School-Age Children

HOUSTON, TX — Neurocare Plus and SCLA Management is actively recruiting children and adolescents ages 12-17 for a new clinical research study evaluating the safety and effectiveness of an investigational migraine treatment. The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses, which occurs in approximately four to 11 percent of elementary school-aged children and eight to 15 percent of high school-aged adolescents. This multicenter, placebo controlled, Phase 3 clinical trial is studying rimegepant as a potential acute treatment to help stop a migraine attack when it occurs.

Nicolas Nammour, MD, Neurocare Plus, said, “Children/Adolescents and their parents may not realize that symptoms such as head pain, nausea and vomiting and sensitivity to light and sound may be migraine. Migraine can be debilitating in younger individuals and it often goes undiagnosed because they have a more difficult time understanding and expressing their pain. There are limited treatment options available for migraine for children and adolescents, so we are hopeful rimegepant may help them get relief and return more quickly to their daily lives.”

Clinicians at Neurocare Plus are now seeking eligible participants for the study. To enroll, participants must be between age 12 and 17, have at least one migraine per month, and have at least a six-month history of migraine. For more information about participating in the study at Neurocare Plus, call (713) 487-8680, visit Neurocare Plus or visit www.pediatricmigrainestudy.com.

Clinical Trial Details

Neurocare Plus is one of more than 90 sites in the U.S. participating in the study. The study is sponsored by New Haven-based Biohaven Pharmaceuticals. The study will enroll approximately 1,200 participants between the ages of 12 and 17 who will receive rimegepant or placebo for the investigational treatment of up to two migraine attacks of moderate to severe intensity. The effectiveness of rimegepant compared to placebo will be measured by freedom from pain at two hours post-dose.

About Migraine in Children and Adolescents

Migraine is a debilitating neurological disease that impacts nearly 40 million people in the United States. In younger individuals, usually those under 15 years of age, migraine attacks may be bi-lateral (felt on both sides of the head) or unilateral (felt on only one side of the head), and may be non-throbbing. The child may look ill and pale, may feel dizzy, have blurred vision, and fever. Nausea and vomiting are frequent, particularly in young children (defined as seven years of age). Individuals with migraine tend to avoid light (photophobia), noise (phonophobia), strong odors, and movement.

About Biohaven

Biohaven is a global commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation™ portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as VYDURA® for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month) and a broad pipeline of late-stage product candidates across five distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine and other CGRP-mediated diseases; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; myeloperoxidase (MPO) inhibition for amyotrophic lateral sclerosis; Kv7 ion channel activators for focal epilepsy and neuronal hyperexcitability, and myostatin inhibition for neuromuscular diseases. More information about Biohaven is available at www.biohavenpharma.com.